[Lab] 20th independent test on FGP — 98.6% on a claimed 98.0%, and the trend is the interesting part
Title says it — 20th independent test on FGP — 98.6% on a claimed 98.0%, and the trend is the interesting part — so here is the boring supporting detail that makes it worth anything.
98.6% and 98.0% — those are the numbers, and they are the ones I am willing to defend.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Tell me where this is wrong. That is the useful part of posting it.
- FGFGP source pageFlourishglobal Peptide Biotech (Chengdu) Co., Ltd. · Chengdu · 89% here, rank 20 · shop at flourishglobalpeptide.net →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
the monotherapy numbers are modest and that is not the point